Chemours Reports Q1 2026 Earnings and Provides Segment Performance Details
Chemours (CC) reported strong performance in its TSS segment with a 22% year-over-year sales increase and a 33% adjusted EBITDA margin. The TT segment also outperformed expectations due to pricing actions and cost management. The APM segment faced a $25 million headwind from a production outage but expects recovery in the second half of 2026.
Tickers: $CC
Topics: earnings ebitda guidance sales segment performance